Myelodysplastic Syndromes

Myelodysplastic syndromes (MDS) are clonal hematopoietic malignancies, characterized by ineffective hematopoiesis, cytopenia, unilineage or multilineage dysplasia, with increased susceptibility to acute myeloid leukemia (AML).

Cytogenetic studies play a key role in the evaluation of patients with MDS; study results are used to establish a diagnosis, stratify patients into prognostic groups, guide medical management, and monitor disease progression. Clonal abnormalities are observed in ~50% of cases evaluated by metaphase cytogenetic analysis and in up to 80% of cases evaluated by cytogenomic single nucleotide polymorphism (SNP) microarray.

Tabs Content
Content Review: 
July 2017

Last Update: October 2019